Use of livers from hepatitis B core antibody positive donors in living donor liver transplantation

Hepato-Gastroenterology

Volumn 57, Issue 102-103, 2010, Pages 1268-1271

  Yaprak, Onur ^a   Dayangac, Murat ^a   Balci, Deniz ^a   Demirbas, Tolga ^a   Yuzer, Yildiray ^a   Tokat, Yaman ^a  

^a FLORENCE NIGHTINGALE HOSPITAL   (Turkey)

Author keywords

Anti HBc positive donor; De novo hepatitis B; Liver transplantation

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; LAMIVUDINE; VIRUS DNA;

ADULT; AGED; ARTICLE; CADAVER DONOR; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER; LIVER FUNCTION; LIVER GRAFT; LIVER TRANSPLANTATION; LIVING DONOR; LIVING DONOR LIVER TRANSPLANTATION; MALE; MONOTHERAPY; PRIORITY JOURNAL; RISK ASSESSMENT; SEROLOGY; VIRUS TRANSMISSION;

ADULT; AGED; DNA, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HUMANS; LAMIVUDINE; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED;

EID: 79251566144     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Chen YS, Wang CC, de Villa VH, Wang SH, Cheng YF, Huang TL, Jawan B, Chiu KW, Chen CL: Prevention of de novo hepatitis B virus infection in living donor liver transplantation using hepatitis B core antibody positive donors. Clin Transplant 2002; 16:405-409.
2. Dickson RC, Everhart JE, Lake JR, Wei Y, Seaberg EC, Wiesner RH, Zetterman RK, Pruett TL, Ishitani MB, Hoofnagle JH: Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology 1997; 113:1668-1674.
3. Lee KH, Wai CT, Lim SG, Manjit K, Lee HL, Da Costa M, Quak SH, Tan KC: Risk for de novo hepatitis B from antibody to hepatitis B core antigen-positive donors in liver transplantation in Singapore. Liver Transpl 2001; 7:469-470.
4. Crespo J, Fâbrega E, Casafont F, Rivero M, Heras G, de la Peña J, de la Cruz F, Pons-Romero F: Severe clinical course of de novo hepatitis B infection after liver transplantation. Liver Transpl Surg 1999; 5:175-183.
5. Dodson SF, Bonham CA, Geller DA, Cacciarelli TV, Rakela J, Fung JJ: Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors. Transplantation 1999; 68:1058-1061.
6. Douglas DD, Rakela J, Wright TL, Krom RA, Wiesner RH: The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient. Liver Transpl Surg 1997; 3:105-111.
7. Wachs ME, Amend WJ, Ascher NL, Bretan PN, Emond J, Lake JR, Melzer JS, Roberts JP, Tomlanovich SJ, Vincenti F, et al: The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-) organ donors. Transplantation 1995; 59:230-234.
8. Dodson SF, Issa S, Araya V, Gayowski T, Pinna A, Eghtesad B, Iwatsuki S, Montalvo E, Rakela J, Fung JJ: Infectivity of hepatic allografts with antibodies to hepatitis B virus. Transplantation 1997; 64:1582-1584. (Pubitemid 28047387)
9. Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seu P, Yersiz H, Goss JA, Schmidt P, Pakrasi A, Artinian L, Murray NG, Imagawa DK, Holt C, Goldstein LI, Stribling R, Busuttil RW: Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998; 28:585-589.
10. Yen RD, Bonatti H, Mendez J, Aranda-Michel J, Satyanarayana R, Dickson RC: Case report of lamivudine-resistant hepatitis B virus infection post liver transplantation from a hepatitis B core antibody donor. Am J Transplant 2006; 6:1077-1083.
11. Prieto M, Gómez MD, Berenguer M, Córdoba J, Rayón JM, Pastor M, García-Herola A, Nicolás D, Carrasco D, Orbis JF, Mir J, Berenguer J: De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population. Liver Transpl 2001; 7:51-58.
12. Nery JR, Nery-Avila C, Reddy KR, Cirocco R, Weppler D, Levi DM, Nishida S, Madariaga J, Kato T, Ruiz P, Schiff E, Tzakis AG: Use of liver grafts from donors positive for antihepatitis B-core antibody (anti-HBc) in the era of prophylaxis with hepatitis-B immunoglobulin and lamivudine. Transplantation 2003; 75:1179-1186.
13. De Maria N, Idilman R, Colantoni A, Harig JM, Van Thiel DH: Antibody response to hepatitis B virus vaccination in individuals with hepatitis C virus infection. Hepatology 2000; 32:444-445.
14. Loss GE Jr, Mason AL, Nair S, Blazek J, Farr G, Guo L, Cohen AJ, Eason JD: Does lamivudine prophylaxis eradicate persistent HBV DNA from allografts derived from anti-HBc-positive donors?. Liver Transpl 2003; 9:1258-1264.
15. Umeda M, Marusawa H, Ueda M, Takada Y, Egawa H, Uemoto S, Chiba T: Beneficial effects of short-term lamivudine treatment for de novo hepatitis B virus reactivation after liver transplantation. Am J Transplant 2006; 6:2680-2685.
16. Suehiro T, Shimada M, Kishikawa K, Shimura T, Soejima Y, Yoshizumi T, Hashimoto K, Mochida Y, Maehara Y, Kuwano H: Prevention of hepatitis B virus infection from hepatitis B core antibody-positive donor graft using hepatitis B immune globulin and lamivudine in living donor liver transplantation. Liver Int 2005; 25:1169-1174.